Sutro Biopharma, Inc. (STRO) Tops Q2 EPS by 27c
Tweet
Share
E-mailGet Alerts STRO Hot Sheet
Join SI Premium – FREE
Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q2 EPS of ($0.14), $0.27 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $63.74 million versus the consensus estimate of $15.79 million.
For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Travere Therapeutics (TVTX) PT Raised to $65 at Guggenheim
- BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance
- McCormick & Co. (MKC) Tops Q2 EPS by 10c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
